Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 33-year-old attempted hair regrowth after 10 years of baldness using topical finasteride, minoxidil, micro-needling, a laser cap, and later oral dutasteride. They noticed some regrowth, especially vellus hairs, and are considering a hair transplant or other treatments despite side effects.

A 42-year-old is using dutasteride, oral and topical minoxidil, ketoconazole, and a dermaroller for hair loss, with noticeable progress after six months. They are questioning if further gains are possible and considering stopping the dermaroller, as advised that future improvements may only involve hair thickening.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A user is using finasteride, minoxidil, and a dermastamp for hair regrowth. They report itchy scalp but see positive results.

The user shared their journey with hair loss, using minoxidil initially, then adding microneedling and finasteride, and finally undergoing a hair transplant. They expressed regret for not using finasteride earlier due to fear of side effects and found the combination of treatments effective in the end.

RU58841 is discussed for hair loss treatment, with questions about its legitimacy from RUdirect. Minoxidil and finasteride are also mentioned as treatments.

DIM is suggested to help with estrogen metabolism for those on finasteride or dutasteride, potentially reversing side effects like fat gain and mood changes. Some users doubt its effectiveness, recommending lifestyle changes or consulting a doctor instead.

Topical RU58841 is discussed for hair loss treatment, with a focus on brands available in Europe that have low systemic absorption. Users suggest mixing your own solution to control vehicle and dosage, and mention different brands like Actifolic and Biolabshop.

Eucapil/fluridil is discussed as a potential treatment for hair loss, with questions about its effectiveness and why it isn't a primary treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

The user has been using 1.5mg finasteride daily for four months and added minoxidil with a dermaroller for one month but stopped due to eye floaters. There is some improvement in hair regrowth, and suggestions include continuing treatment, using ketoconazole shampoo, and considering other supplements like vitamin D, saw palmetto, and biotin.

After four months of using minoxidil, finasteride, tretinoin, and microneedling, fine white fuzz appeared on bald patches. There is uncertainty if this fuzz will develop into full hair.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

A user, almost 50, has been using finasteride for 30 years and recently added oral dutasteride to address hair recession. They are now trying a new treatment stack including Minoxidil, Dutasteride, Melatonin, Rosemary oil, and Bimatoprost, along with derma stamping and Ketoconazole shampoo.

A 35-year-old male used oral finasteride and topical minoxidil, later transitioning to oral minoxidil, to stop hair loss and improve hair density. He plans a future hair transplant and experienced temporary libido changes but no permanent side effects.

Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation discusses using pyrilutamide with finasteride and minoxidil for hair loss treatment. The user is concerned about potential side effects and mentions using 1 mg finasteride on alternate days and daily minoxidil.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

A 35-year-old man had a 6400 graft hair transplant in Turkey after years of baldness, using finasteride, oral and topical minoxidil, and scalp micropigmentation. He is satisfied with the progress and plans further SMP touch-ups to enhance results.

The user is seeking a substitute for Tretinoin to enhance the effectiveness of Minoxidil for hair loss. They are considering using Retinol as an alternative.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

PP405 is being discussed as a potential treatment for hair loss, with uncertainty about its effectiveness compared to existing treatments like finasteride, dutasteride, and minoxidil. There is cautious optimism, but its impact on hair transplants remains unclear.

Finasteride improved scalp hair but thinned beards for some users. Some suggest trying minoxidil on the beard, though results vary.

The user experienced significant hair regrowth over four months using oral finasteride, oral minoxidil, micro-needling, and rosemary oil. They reported no side effects and emphasized the importance of continuing the treatment to maintain results.